Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.160
+0.040 (3.57%)
Aug 27, 2026, 4:00 PM EDT - Market closed
Lineage Cell Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 13.08 | 14.56 | 9.5 | 8.95 | 14.7 | 4.34 | |
Revenue Growth | 19.87% | 53.24% | 6.19% | -39.16% | 238.70% | 137.73% |
Cost of Revenue | 20.59 | 17.88 | 12.81 | 16.38 | 0.73 | 1.43 |
Gross Profit | -7.51 | -3.32 | -3.31 | -7.43 | 13.98 | 2.92 |
Selling, General & Admin | 19.35 | 18.46 | 18.17 | 13.77 | 22.51 | 18.21 |
Research & Development | - | - | - | - | 13.99 | 33.91 |
Operating Expenses | 19.35 | 18.46 | 18.17 | 13.77 | 36.5 | 52.13 |
Operating Income | -26.85 | -21.78 | -21.48 | -21.2 | -22.52 | -49.21 |
Interest & Investment Income | 1.54 | 1.69 | 1.72 | 1.63 | 0.83 | 0 |
Currency Exchange Gain (Loss) | 1.42 | 2.15 | -0.27 | -1.04 | -2 | 1.49 |
Other Non Operating Income (Expenses) | -13.52 | -35.86 | 1.46 | 0.54 | 0.07 | 0.21 |
EBT Excluding Unusual Items | -37.41 | -53.8 | -18.57 | -20.08 | -23.62 | -47.52 |
Gain (Loss) on Sale of Investments | 0.02 | -0.01 | -0.01 | -0.18 | -2.19 | 3.73 |
Asset Writedown | - | -14.84 | - | - | - | - |
Legal Settlements | - | - | - | -3.53 | - | - |
Other Unusual Items | - | - | - | 0.5 | - | 0.52 |
Pretax Income | -37.39 | -68.65 | -18.58 | -23.28 | -25.81 | -43.27 |
Income Tax Expense | -5.28 | -5.28 | - | -1.8 | 0.54 | - |
Earnings From Continuing Operations | -32.11 | -63.37 | -18.58 | -21.48 | -26.35 | -43.27 |
Minority Interest in Earnings | -0.16 | -0.17 | -0.03 | -0.01 | 0.08 | 0.25 |
Net Income | -32.26 | -63.53 | -18.61 | -21.49 | -26.27 | -43.02 |
Net Income to Common | -32.26 | -63.53 | -18.61 | -21.49 | -26.27 | -43.02 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 240 | 230 | 200 | 173 | 170 | 165 |
Shares Outstanding (Diluted) | 240 | 230 | 200 | 173 | 170 | 165 |
Shares Change | 8.73% | 14.95% | 15.94% | 1.69% | 3.22% | 9.64% |
EPS (Basic) | -0.13 | -0.28 | -0.09 | -0.12 | -0.15 | -0.26 |
EPS (Diluted) | -0.19 | -0.28 | -0.09 | -0.12 | -0.15 | -0.26 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -24.39 | -19.44 | -23.66 | -29.24 | 0.65 | -23.9 |
Free Cash Flow Per Share | -0.10 | -0.08 | -0.12 | -0.17 | 0.00 | -0.14 |
Gross Margin | -57.36% | -22.80% | -34.81% | -83.07% | 95.05% | 67.15% |
Operating Margin | -205.23% | -149.62% | -226.11% | -237.04% | -153.17% | -1133.63% |
Profit Margin | -246.58% | -436.47% | -195.91% | -240.20% | -178.69% | -990.99% |
Free Cash Flow Margin | -186.42% | -133.56% | -249.05% | -326.89% | 4.39% | -550.59% |
EBITDA | -26.11 | -21.08 | -20.87 | -20.51 | -21.79 | -48.34 |
EBITDA Margin | -199.58% | -144.82% | -219.70% | -229.30% | -148.22% | - |
D&A For EBITDA | 0.74 | 0.7 | 0.61 | 0.69 | 0.73 | 0.87 |
EBIT | -26.85 | -21.78 | -21.48 | -21.2 | -22.52 | -49.21 |
EBIT Margin | -205.23% | -149.62% | -226.11% | -237.04% | -153.17% | - |
Revenue as Reported | 13.08 | 14.56 | 9.5 | 8.95 | 14.7 | 4.34 |